Press release
Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
Advancements in formulation technology open new avenues for revenue generationMOUNTAIN VIEW, Calif. – November 21, 2011 – Alarm bells are ringing loud and clear as diabetes has grown to epidemic proportions worldwide, triggering intensive ophthalmic research into vision-compromising comorbidities. The Centers for Disease Control and Prevention predicts that diabetic retinopathy will triple from 5.5 million in 2005 to 16.0 million in 2050. As diabetes is the leading cause of blindness in working age people, improved treatments are urgently needed. The presence of novel biopharmaceuticals as well as advancements in formulation technology has boosted the outlook for the U.S. retinal therapeutics market.
New analysis from Frost & Sullivan’s (http://www.pharma.frost.com) U.S. Retinal Therapeutics Market research estimates revenues in the age-related macular degeneration (AMD) segment of the market to reach $2.26 billion by 2016. Revenues in the diabetic macular edema (DME) segment are expected to reach $455.2 million by 2016.
If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at britni.myers@frost.com, with your full name, company name, title, telephone number, company email address, company Web site, city, state and country.
“While the cannibalization of Roche/Genentech profits (i.e., Avastin and Lucentis) may sound like a market challenge for that company versus a driver for the market, the very availability of these two highly effective, novel medications is expected to continue to drive this previously underserved market,” said a Frost & Sullivan research analyst. “Moreover, the absence of laws and regulations permitting the manufacture of generic equivalents of biologics ensures that these therapies will remain under patent protection until 2019.”
Developing therapies to treat diseases of the back of the eye is complex and, as a result, there is strong market opportunity for wet AMD drugs. The scope for wet AMD drugs such as Lucentis and Avastin is being further expanded by penetration into other back-of-the-eye conditions such as DME and retinal vein occlusion.
Another factor uplifting market prospects is the aging baby boomer population in the United States, which will create a demand upsurge for ophthalmics that improve, restore and preserve sight. Ease of use of therapy is also expected to be of considerable importance among this growing elderly patient base. This has opened up new avenues of opportunity for pharmaceutical and drug delivery companies, enabling a boost in their revenues.
Established treatment alternatives impede the success of new DME therapies. Although Lucentis may achieve its primary endpoint in its trials for DME, it is unlikely to achieve the same level of commercial success it did with wet AMD due to the cost and relative effectiveness of existing treatment options. Lucentis must demonstrate significant clinical efficacy to justify the costly monthly injections required to sustain visual acuity gains in the DME patient population.
Long, drawn out and costly clinical trials will deter new market entrants. In addition, difficulties in finding patients willing to participate in clinical trials and the lack of funds for costly and lengthy trials limit drug companies' abilities to introduce new products into the market. Several pharmaceutical and drug delivery companies are ramping up research efforts to improve the delivery of drugs to the back of the eye.
“Trends indicate that Avastin will remain the most-utilized pharmacologic therapy for the treatment of retinal vascular disease,” said the research analyst. “By 2016, Regeneron is expected to supplant Roche/Genentech as the largest revenue contributor to the market.”
U.S. Retinal Therapeutics Market is part of the Pharmaceuticals & Biotechnology Growth Partnership Service program, which also includes research in the following markets: U.S. Skin Cancer Market; Global CRO Market: Quantitative Assessment; U.S. Contract Research Outsourcing Market; U.S. Asthma and COPD Market; and U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
U.S. Retinal Therapeutics Market
N85D
Contact:
Britni Myers
Corporate Communications – North America
P: 210.477.8481
F: 210.348.1003
E: britni.myers@frost.com
http://www.frost.com
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.
Frost & Sullivan
331 E. Evelyn Ave. Suite 100
Mountain View, CA 94041
Britni Myers
Corporate Communications
210-477-8481
britni.myers@frost.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant here
News-ID: 201504 • Views: …
More Releases from Frost & Sullivan
As a Third Generation of Technology Emerges, Where is the Robotic Assisted Surge …
Funding and investment create tremendous growth opportunities for robotic assisted technology, finds Frost & Sullivan’s Transformational Health Team
SANTA CLARA, CA. – November 21, 2016 – Today, only 5 percent of U.S. surgery procedures are performed with a robotic assisted surgical device (RASD). New market entrants are expanding the genre of surgical procedures currently available. Further, bundled payments could make robot-assisted surgical procedures more cost effective than conventional surgical techniques. Success,…
Biometric Wearables to Disrupt the Automotive Industry
Tremendous growth opportunities arise as automakers partner with technology providers, finds Frost & Sullivan’s Intelligent Mobility team
London – November 16, 2016 – Advancements in biometrics will radically transform the driving experience, health wellness and wellbeing (HWW), and security of vehicles by 2025. As one in three new passenger vehicles begin to feature fingerprint recognition, iris recognition, voice recognition, gesture recognition, heart beat monitoring, brain wave monitoring, stress detection, fatigue monitoring,…
More Releases for DME
Dimethyl Ether (DME) & R-DME Market Expansion and Future Trends | 2025 To 2034 O …
The Global Dimethyl Ether (DME) & R-DME Market Size, Scope, and Forecast 2025-2034 report is now part of Exactitude Consultancy's Market Research collection. Industry experts and researchers provide an authoritative and concise analysis of the Dimethyl Ether (DME) & R-DME Market, covering key aspects such as growth drivers, challenges, restraints, developments, and opportunities. This report delivers a precise evaluation of shifting market dynamics and emerging trends. Additionally, it offers a…
DME Service Solutions Partners with the AAHomecare
DME Service Solutions, a leader in providing B2B outsourcing solutions specializing in healthcare, is thrilled to announce its partnership with the American Association for Homecare (AAHomecare). This partnership allows DME Service Solutions to engage with a community dedicated to advancing quality care and operational efficiency in the homecare industry.
AAHomecare has served the home medical equipment (HME) industry for nearly four decades, advocating for improved access to quality homecare products…
Global Airport Ground DME Market Analysis (2020-2025)
Global Info Research offers a latest published report on Airport Ground DME Analysis and Forecast 2020-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Airport Ground DME Concentrate players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
Click to view the full report TOC, figure…
Global Durable Medical Equipment (DME) Market Insights, Forecast
Durable Medical Equipment (DME) is a medical equipment that durable, can be used in the home and have at least 3 years of life expectancy. The prevalence of chronic conditions, such as heart disorders, cancer, gynecological disorders, and neurological disorder is on a rise, demand of long term care and hospitalization for treatment of these disorders is anticipated to facilitate the demand for durable medical equipment. The global Durable Medical…
Durable Medical Equipment (DME) Global Market 2019
Press Release – 30 Jan 2019
Research and Development News --
. .
Latest Update "Global Durable Medical Equipment (DME) Market By Type, By Therapeutic and monitoring Devices Type, By End User, By Region, By Country (2018 Edition) - Forecast to 2023-By Type (Personal Mobility devices, Therapeutic and Monitoring Devices, Medical Furniture, Others), By Sub-Type (Oxygen Equipment, Blood Sugar Monitors, Continuous Passive Motions, Nebulizers, Other Devices), By End User (Hospitals and Clinics,…
Dimethyl Ether (DME) Market - Asia Pacific is a major market for DME | Mitsubish …
Majority of the DME manufactured these days is an end-product of two-step process where the first step involves methanol generation with the help of natural gas or coal being used a feedstock. And the second step involves dehydration of methanol for the production of DME. Dimethyl Ether has the potential of replacing diesel in the conventional engines with small modifications that need to be made in the fuel injecting systems.…